RxDoctor Payments Data

Krishna Nagendran, MD

Interventional Cardiology · Naperville, ILNPI 1265674691

Payments from drug & device makers

$38,852in general payments, 2019–2025

Across 347 payments — averaging $111.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$16K
  • Edwards Lifesciences$11K
  • Imperative Care, Inc$3K
  • Angiodynamics, Inc.$2K
  • Bard Peripheral Vascular, Inc.$497
  • Inari Medical, Inc.$441
  • plus $5K from 42 others

What the payments were for

  • Consulting fees$10,70028%
  • Speaking & faculty fees$15,40040%
  • Food & beverage$12,57032%
  • Education$570%
  • Entertainment$1240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,852 in reported general payments places this provider in the 75th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$463,526
Medicare patients
782
Services billed
4,691

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban609$482,737
EntrestoSacubitril/Valsartan288$219,345
XareltoRivaroxaban144$117,208
FarxigaDapagliflozin Propanediol79$55,759
Repatha SureclickEvolocumab57$46,114
Praluent PenAlirocumab37$22,190
BrilintaTicagrelor26$15,896
Repatha PushtronexEvolocumab15$11,802
JardianceEmpagliflozin12$10,629
Metoprolol Succinate924$8,266
ClopidogrelClopidogrel Bisulfate557$4,324
Ranolazine ErRanolazine33$3,601
Atorvastatin Calcium544$3,295
Chlorthalidone240$3,160
Cilostazol162$2,933

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$49$482,737609 claims
NovartisEntresto$16,403$219,345288 claims
Johnson & JohnsonXarelto$221$117,208144 claims
AstraZenecaFarxiga, Brilinta$33$71,655105 claims
Boehringer IngelheimJardiance$139$10,62912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Naperville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →